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The  clinical  relevance  of the  interaction  between  human  cancer  and  neutrophils  has  recently  begun
to emerge.  This  review  will  focus  on recently  published  articles  regarding  immunomonitoring  of  neu-
trophils  in  blood  and  tumor  tissue  in  clinical  trials  comprising  the  main  human  tumor  types,  with  a  strong
emphasis  on  independent  prognostic  relevance  assessed  by  multivariate  analyses.
The  prognostic  role  of  tumor-inﬁltrating  neutrophils,  elevated  blood  neutrophils  and  elevated  blood
neutrophil/lymphocyte  ratio  has  been  associated  with  poor  clinical  outcome  in  several  human  cancers,
most notably  in renal  cell  carcinoma,  melanoma,  colorectal  cancer,  hepatocellular  carcinoma,  cholangio-
carcinoma,  glioblastoma,  GIST,  gastric,  esophageal,  lung,  ovarian  and  head  and  neck  cancer.  A striking
ﬁnding  is  the  notion  that  high  baseline  neutrophil  count  in  either  tumor  or blood,  or  both,  was  identiﬁed
as strong,  independent  risk  factor  for  poor  outcome  in  multivariate  analyses,  and  the  negative  prognostic
impact of  neutrophils  was  not  eliminated  by increasing  the  dose  of  cytokines,  chemotherapy,  or  targeted
therapy.  For  several  cancers,  patients  beneﬁt  most  from  therapy  if  baseline  neutrophil  was  low.  Thus,
baseline  neutrophils  over-ride  nadir  counts  in  prognostic  signiﬁcance.
In summary,  a proportion  of  patients  who  do  not  experience  beneﬁt  from  surgery  or medical  interven-
tion may  be  associated  with  a  worst  prognosis  because  they  are  characterized  by  baseline  tumor-related
neutrophilia  protecting  them  from  beneﬁt  from  therapy.  Further  research  to unraveling  the  cancer  biology
and  new  treatment  options  is  encouraged.. Introduction
Neutrophils are the most common leukocyte subset in the
loodstream. Neutrophils are short-lived white blood cells derived
rom bone marrow myeloid precursors. Attention to their poten-
ial role in human cancer has largely been ignored. New ﬁndings
uggest that the role of neutrophils in cancer-related inﬂamma-
ion may  need careful reappraisal of inﬁltration, polarization, and
rognostic signiﬁcance of neutrophils in human cancer [1].
Previous older studies have advocated a role of direct or
ntibody-dependent killing of tumor cells by neutrophils (recently
eviewed in [2]). One of the oldest reports of a potential anti-
umor effect of the innate immune system comes from William
oley (reviewed in [3]). He observed that patients with febrile
treptococcal infection within an ulcerated tumor had a better
rognosis than patients with uninfected tumors. For obvious rea-
ons, he was unable to explain the observations in immunology
erms. Since Coley’s initial reports, knowledge about mechanisms
n cellular immunity has increased. However, cancer therapy for
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invasive human cancer utilizing a neutrophil-mediated approach
has not yet been established [4].
This review will focus on recently published articles regarding
immunomonitoring of neutrophils in blood and tumor tissue in
clinical trials comprising the main human tumor types, with a
strong emphasis on independent prognostic relevance assessed by
multivariate analyses.
2. Kidney cancer
The ﬁrst report of neutrophils as an adverse prognostic fac-
tor for patients with metastatic renal cell carcinoma (mRCC)
was  published in 1996 by Lopez Hanninen et al. [5], Table 1.
In a series of 215 consecutive patients with mRCC treated with
interleukin-2 (IL-2) based immunotherapy, elevated baseline blood
neutrophils (>6 × 109/L) was identiﬁed as an independent risk
factor of short overall survival (OS). Subsequently, the Groupe
Franc¸ ais d‘Immunothérapie published in 2002 results compris-
ing 782 patients in successive multicenter trials using cytokine
regimens [6]. Analyses were performed on this large prospective
2013 Elsevier Ltd. Open access under CC BY-NC-ND license.database to identify prognostic factors for survival and predic-
tive factors for progression. Elevated baseline neutrophil count
(>7.5 × 109/L) was  independently predictive of short survival in a
multivariate analysis. The authors also identiﬁed four independent
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Table 1
Landmark studies evaluating the prognostic role of neutrophils in clinical trials.
Pub year Tumor type N Parameter
analyzed
MoAb
IHC
Cut-offs Clinical
endpoint
Therapy Study design Signiﬁcant in
multivariate analysis
1996 [5] mRCC 215 Blood N NA >6 × 109/L OS Cytokines Retrospective p = 0.006
2002  [6] mRCC 782 Blood N NA >7.5 × 109/L OS Cytokines Prospective HR 1.4, p = 0.004
2006  [7,10] mRCC 120 Blood N
Tumor N CD66b
>6 × 109/L
>0 cells/mm2
OS Cytokines Prospective HR 2.0, p = 0.015
HR 2.3, p = 0.001
2007  [13] mRCC 120 Blood N NA >4.5 × 109/L PFS TKI Prospective HR 2.31, p = 0.002
2009  [14] mRCC 645 Blood N NA >ULN OS TKI Consecutive pts
multiinstitutional
HR 2.42, p < 0.001
2012  [16] mRCC 109 NLR NA ≤3 PFS
OS
TKI Retrospective HR 0.285, p < 0.001
HR 0.3, p = 0.043
2009  [17] RCC 121 Tumor N CD66b >0 cells/mm2 RFS
CSS
OS
Surgery Retrospective HR 3.0, p < 0.001
HR 3.5, p < 0.001
HR 3.1, p < 0.001
2005  [19] MMM  321 Blood N NA >ULN OS Cytokines Prospective HR 1.4, p = 0.002
2007  [20] MMM  316 Blood N NA ≥7.5 × 109/L OS Biochemo Prospective HR 1.5, p = 0.02
2012  [21] Melanoma 183 Tumor N CD66b Absent vs. present CSS Surgery Retrospective HR 3.13, p = 0.004
2012  [22] CRC 229 Tumor N CD66b >60 per TMA  spot OS Surgery Retrospective HR 2.04, p = 0.01
2012  [26] mCRC 170 Blood N NA >ULN OS Chemo Retrospective HR 2.18, p = 0.014
2012  [27] mCRC 50 NLR NA ≥4 OS Chemo Retrospective HR 4.39, p = 0.0013
2012  [28] mCRC 92 NLR NA >5 OS RFA Retrospective HR 3.59, p = 0.039
2011  [29] mCRC 171
178
NLR NA >5 OS Chemo Training set
Validation set
HR 1.7, p = 0.002
p < 0.0001
2008  [30] HCC 96 NLR NA ≥5 DFS Surgery Retrospective HR 2.59, p = 0.02
2011  [31] HCC 281 Tumor N CD66b >70th percentile RFS
OS
Surgery Retrospective HR 1.845, p = 0.008
HR 2.578, p < 0.001
2011  [32] HCC 238 Peritumor
N
CD15 >54/ﬁeld DFS
OS
Surgery Retrospective HR 2.718, p = 0.0022
HR 2.816, p = 0.0011
2012  [33] HCC 240 Tumor N CD66b >12 cells per mm core RFS Surgery Retrospective HR 1.45, p = 0.036
2012  [35] ICC 123 Tumor N CD66b >86 cells per mm core OS Surgery Retrospective HR 1.76, p = 0.007
2012  [36] Gastric 115
97
Tumor N CD15 >21.6 cells/HPF OS Surgery Training set
Validation set
HR 1.943, p = 0.027
p  = 0.032
2007  [38] Gastric 1220 NLR NA ≥2.5 OS Chemo Prospective HR 1.52, p = 0.77 × 10−8
2010 [39] Gastric 1028 NLR NA ≥4 OS Surgery Retrospective HR 1.845, p = 0.003
2011  [41] Esophageal 295 NLR NA ≥5 DFS
OS
Surgery Retrospective HR 2.26, p < 0.0001
HR 2.32, p < 0.0001
2011  [45] HNSCC 40 Tumor N CD66b ≥Medium OS RT + chemo Retrospective HR 2.61, p = 0.048
2011  [46] Naso-pharyngeal 363 NLR NA >3.73 CSS RT + chemo Retrospective HR 1.74, p = 0.008
2007  [48] GIST 232 Blood N NA >5 × 109/L PFS TKI Prospective HR 2.0789, p = 0.02
2010  [50] GIST 1640 Blood N NA Continuous variable PFS
OS
TKI Metaanalysis p < 0.05
p < 0.05
1995  [54] NSCLC 1052 Blood N NA >75% percentile OS Chemo Prospective RR 1.31, p = 0.02
2000  [55] SCLC 763 Blood N NA <75% percentile Response
OS
Chemo Prospective p = 0.04
HR 0.8, p = 0.05
2009  [56] NSCLC 388 Blood N NA >4.5 × 109/L PFS
OS
Chemo Prospective p = 0.024
HR 1.67, p = 0.0008
2012  [60] Ovarian 964 Blood N NA >3.9 × 109/L PFS Chemo Prospective p < 0.001
RCC, renal cell carcinoma; mRCC, metastatic renal cell carcinoma; MMM,  metastatic malignant melanoma; CRC, colorectal carcinoma; mCRC, metastatic colorectal carcinoma; HCC, hepatocellular carcinoma, ICC, intrahepatic
cholangiocarcinoma; HNSCC, head and neck squamous cell carcinoma, GIST, gastrointestinal stromal tumors; NSCLC non-small-cell lung cancer; SCLC, small cell lung cancer; N, neutrophils; NLR, neutrophil–lymphocyte ratio;
MoAb,  monoclonal antibody; IHC, immunohistochemistry; OS, overall survival; RFS, recurrence-free survival; DFS, disease-free survival; CSS, cancer-speciﬁc survival; PFS, progression-free survival; HPF, high power ﬁelds; TKI,
tyrosinekinase inhibitors;RT, radiotherapy; RFA, radio frequency ablation; HR, hazard ratio.
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actors predictive of rapid progression under cytokine treatment:
resence of hepatic metastases, <1 year from renal tumor to
etastases, more than one metastatic site, and elevated baseline
eutrophil counts (>7.5 × 109/L). Patients who combined at least
hree of these factors had >80% probability of rapid progression
espite treatment. The authors stated that these results should
e taken into account when making the decision to treat with
ytokines. The following years the research group from Aarhus Uni-
ersity Hospital in Denmark published their translational results
ased on 443 serial blood samples and 225 serial tumor core biop-
ies obtained at baseline and during treatment with IL-2 based
herapy in 120 consecutive patients with mRCC [7]. The vast major-
ty of these patients were included in phase II trials. Based on
hese analyses, the authors were able to map  the orchestration of
mmune cells in blood and tumor at baseline and during IL-2 based
mmunotherapy [8]. An understanding of IL-2 based immunother-
py as a “targeted therapy” requiring lymphocyte subsets for tumor
ejection emerged from these analyses. In addition, an impor-
ant understanding of the powerful negative impact of neutrophils
lso appeared. The analyses revealed that no blood lymphocyte
ubset was correlated with survival whereas high numbers of
aseline blood neutrophils, on-treatment blood neutrophils and
n-treatment blood monocytes were correlated with short sur-
ival [8]. Low numbers of on-treatment blood neutrophils were
orrelated with response [8]. Evaluating intra-tumoral immune
ells, high numbers of baseline CD57+ natural killer (NK) cells,
aseline CD4+ T-cells, and on-treatment CD3+ T-cells were sig-
iﬁcantly correlated with favorable survival [9] whereas baseline
resence of intratumoral neutrophils was correlated with short
urvival [10]. Thus, neutrophils and monocytes/macrophages were
bad guys” and T cells and NK-cells were “good guys” for the out-
ome of IL-2 based immunotherapy [7]. However, it appeared that
he “bad guys” had stronger prognostic impact than the “good
uys”. Strikingly, in a randomized phase II trial of IL-2 alone versus
L-2 plus histamine [11], patients with high numbers of neu-
rophils in peripheral blood at baseline (>6 × 109/L) and after 8
eeks of treatments (>4.57 × 109/L) had very poor survival, with
pparently no impact of either IL-2-alone or IL-2 plus histamine
reatment, as almost all patients with high blood neutrophils were
ead within 2 years from commencement of therapy [12]. Only
atients with low numbers of blood neutrophils at baseline and
uring treatment achieved long-term survival. In another cohort
f patients treated with low-dose IL-2 based immunotherapy,
ven lower level of blood neutrophils (≥2.19 × 109/L) at week 5
fter commencement of therapy was associated with poor sur-
ival. Thus, patients with blood neutrophils ≥2.19 × 109/L had a
edian survival of 10.9 months whereas patients with blood neu-
rophils < 2.19 had a median survival of 25.1 months [8]. Based
n a ﬁnal multivariate analyses including baseline factors only,
he authors pointed on ﬁve clinical features (performance status,
one metastases, lymph node metastases, low hemoglobin and
igh lactate dehydrogenase) and three supplemental immunolog-
cal features (presence of intratumoral CD66+ neutrophils > 0, high
lood neutrophils > 6.0 × 109/L and low intratumoral CD57+ NK
ells < 50 cells/mm2) as independent prognostic factors of survival
n patients with mRCC receiving IL-2 [10]. These three independent
mmunological parameters had signiﬁcant discriminatory power
s supplemental risk factors in prognostic models based on the
linical risk factors, identifying subgroups within the favorable clin-
cal group with estimated 5-year survival rates of 60%, 25% and
%, respectively. The authors concluded that patients with sev-
ral poor prognostic features, based on clinical risk factors only or
linical risk factors supplemented with immunologic risk factors,
hould not receive IL-2-based immunotherapy [10]. It is notewor-
hy, that these analyses – comprising the vast majority of immune
ell subsets – identiﬁed baseline neutrophils, both in the bloodiology 23 (2013) 200– 207
compartment as well as in the tumor compartment, as an inde-
pendent factor for short survival in patients with metastatic renal
cell carcinoma, and also pointed at on-treatment blood neutrophils
as a risk factor, emphasizing the compelling prognostic relevance
of neutrophils. For comparison, only one lymphocyte subset (intra-
tumoral CD57+ NK cells) was  identiﬁed as an independent factor
for favorable survival.
In the era of targeted therapy, Choueiri et al. evaluated 120
patients with metastatic clear-cell RCC receiving bevacizumab,
sorafenib, sunitinib, or axitinib on prospective clinical trials at
the Cleveland Clinic [13]. Multivariate analysis identiﬁed elevated
baseline neutrophil count (>4.5 × 109/L) as an independent, adverse
prognostic factor for short progression-free survival (PFS). Heng
et al. evaluated prognostic factors for OS in 645 patients with mRCC
treated with vascular endothelial growth factor (VEGF)-targeted
therapy [14]. Data were collected from three US and four Canadian
cancer centers. In addition to well-known clinical risk features, neu-
trophils greater than the upper limit of normal (ULN) and platelets
greater than the ULN were independent adverse prognostic factors.
Patients were segregated into three risk categories: the favorable-
risk group (no prognostic factors), in which 2-year OS was  75%; the
intermediate-risk group (one or two  prognostic factors), in which
2y OS was 53%; and the poor-risk group (three to six prognostic
factors), in which 2y OS was  7%. The major contribution of this pro-
gnostic model is the addition of biological information, i.e., platelet
and neutrophil counts, to the Memorial Sloan Kettering Cancer Cen-
ter prognostic model, which is based on clinical features only. This
model has recently been validated in an independent cohort of
patients [15].
Keizman et al. evaluated the association of pre-treatment neu-
trophil to lymphocyte ratio (NLR) with response rate, PFS and OS
in 109 patients treated with sunitinib for mRCC [16]. A low base-
line blood NLR ≤ 3 was  independently correlated with response to
sunitinib, and independently correlated with favorable PFS and OS.
In non-metastatic, localized, clear cell RCC, the prognostic
importance of intratumoral neutrophils have been assessed by
Jensen et al. [17]. The study comprised 121 consecutive patients
who  had a nephrectomy for localized clear cell RCC. In multivari-
ate analysis, the presence of intratumoral CD66+ neutrophils was
independent prognostic factors signiﬁcantly associated with short
recurrence-free survival, cancer-speciﬁc survival and OS. Applying
the prognostic value of intratumoral neutrophils to the Leibovich
low-/intermediate-risk group showed a 5-year recurrence-free sur-
vival of 53% in patients with presence of intratumoral neutrophils
compared with 87% in patients with absence of intratumoral neu-
trophils. The estimated concordance index was 0.74 using the
Leibovich risk score and 0.80 when intratumoral neutrophils were
added. Thus, patients with intratumoral neutrophils should have
a closer follow-up. Intratumoral neutrophils may also serve as a
new stratiﬁcation factor for randomized trials [17]. In another study
in patients with localized RCC, pre-treatment blood NLR has been
demonstrated as an independent predictor of recurrence [18].
Taken together, the prognostic relevance of neutrophils in
localized and metastatic RCC is important and reveals a sub-
group of patients with a very poor prognosis and only limited
or no effect of cytokine or targeted therapy. Impaired progno-
stic impact has been noted for baseline blood neutrophils (range
4.5–7.5 × 109/L), on-treatment week 5 and week 8 blood neu-
trophils (range 2.19–4.57 × 109/L), and intra-tumoral presence of
neutrophils both in localized and metastatic renal cell carcinoma.
Further research to unravel the underlying biology is encouraged.3. Melanoma
The ﬁrst report of neutrophils as an adverse prognostic factor
for patients with metastatic melanoma (MMM)  was published in
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005 by Schmidt et al. [19]. A total of 321 patients were treated as
art of several phase II protocols with IL-2-based immunotherapy.
 multivariate analysis identiﬁed elevated LDH, elevated baseline
eutrophil counts (>ULN) and poor performance status as indepen-
ent prognostic factors for poor survival. An elevated monocyte
ount could replace the elevated neutrophil count in the model.
atients were assigned to one of three risk groups according to
he cumulative risk deﬁned as the sum of simpliﬁed risk scores
f the three independent prognostic factors. High-risk patients
chieved a median survival of 3.4 months and should probably
ot be offered IL-2-based immunotherapy [19]. The author vali-
ated this ﬁnding in an independent cohort of patients from the
uropean Organization for the Research and Treatment of Cancer
8951-study treated with dacarbazine, cisplatin, and interferon alfa
ith or without interleukin-2 [20]. Two multivariate prognostic
actor analyses were carried out in the model: one with leuko-
yte counts and one with neutrophil counts. A total of 363 patients
ere randomly assigned and baseline blood neutrophil and leuko-
yte counts were available from 316 and 350 patients, respectively.
 high neutrophil count (>7.5 × 109/L) was an independent pro-
nostic factor for short overall survival and a high leukocyte count
>10 × 109/L) was an independent prognostic factor of both short
S and short PFS. Thus, elevated baseline blood neutrophils count
s a validated prognostic factor for poor survival in MMM.
The authors subsequently assessed the prognostic impact of
ntratumoral CD66b+ neutrophils in 183 surgically resected stage
/II melanoma patients. In a multivariate model including ulcera-
ion and melanoma thickness, presence of intratumoral neutrophils
as independently associated with poor relapse-free survival,
elanoma-speciﬁc survival, and OS [21].
Taken together, high neutrophil, monocyte, or leukocyte counts
n peripheral blood and presence of intratumoral neutrophils have
een observed as strong, poor, independent prognostic factors in
atients with melanoma.
. Colorectal cancer
The ﬁrst report of intratumoral neutrophils as an adverse
rognostic factor for patients with colorectal cancer (CRC) was  pub-
ished in 2012 by Hui-Lan Rao et al. [22]. In 229 patients undergoing
rimary and curative resection for CRC, high intratumoral CD66b+
eutrophil was positively correlated with pT status, pM status and
linical stage. In multivariate survival analysis, high intratumoral
eutrophil and pT status were evaluated as an independent progno-
tic factor for adverse OS [22]. Previous evaluations of a prognostic
elevance of intratumoral neutrophils in colorectal cancer have all
een negative in multivariate analyses, probably due to the use of
ematoxylin and eosin (HE) staining [23,24] or elastase staining
nly [25] with no use of immunohstochemistry.
In 2012 blood neutrophils was also identiﬁed as an independent
rognostic marker for poor survival in metastatic CRC [26]. A total
f 170 patients with metastatic CRC treated with FOLFIRI or XELOX
lus anti-VEGF therapy were evaluated. Baseline blood neutrophils
>ULN) was independently associated with poor survival with a
wofold risk of mortality.
Several papers have evaluated the prognostic role of NLR. In
dvanced CRC patients receiving oxaliplatin-based chemotherapy,
n elevated NLR (≥4) independently predicted poor prognosis [27].
levated NLR (>5) also independently predicted poor prognosis
or colorectal liver metastasis after percutaneous radiofrequency
blation [28]. A recent study by Chua et al. evaluating NLR in
nresectable metastatic CRC patients receiving ﬁrst-line palliative
hemotherapy from two independent cohorts of Australian and
anadian patients has identiﬁed and validated baseline blood NLR
>5) to independently predict poor OS [29]. This is the ﬁrst study toiology 23 (2013) 200– 207 203
describe the use of NLR in a non-selected unresectable metastatic
CRC setting for patients receiving ﬁrst-line palliative chemotherapy
to provide useful information regarding prognostication, and the
data were validated in an independent community-based cohort.
Importantly, normalization of the NLR after one cycle of chemother-
apy was  observed in a subset of patients, which resulted in a
2-month PFS improvement (5.8 vs. 3.7 months) compared with
patients without NLR normalization. However, normalization of the
NLR after one cycle of chemotherapy did not result in a statistically
signiﬁcant improvement in OS compared with patients without
NLR normalization. Thus, baseline NLR override nadir counts in
prognostic signiﬁcance.
5. Hepatocellular carcinoma and cholangiocarcinoma
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide. Gomez et al. published in 2008 the
observation in 96 HCC patients undergoing hepatic resection
that preoperative NLR (≥5), microvascular invasion and positive
resection margin were adverse predictors of OS [30]. In multivariate
analysis NLR ≥ 5 was an independent predictor of poor disease-free
survival, but not for OS. This was the ﬁrst study to implicate the
relationship of an elevated preoperative NLR and a poorer prog-
nosis for patients undergoing potentially curative liver resection
for HCC. In 2011 and 2012 several studies have shed more light
on the prognostic relevance of neutrophils in HCC and cholangio-
carcinoma. Li et al. evaluated two  independent cohorts of patients
that included a total of 281 patients undergoing curative resection
of HCC [31]. Increased intratumoral CD66+ neutrophils were inde-
pendently associated with poor recurrence-free survival and poor
OS in a multivariate analysis. This was  the ﬁrst study to identify
intratumoral neutrophils as an independent prognostic factor for
HCC after resection. Subsequently Kuang et al. evaluated a total of
238 HCC patients [32]. Intratumoral neutrophils count visualized by
immunohistochemical staining of CD15 and SuperArray Real-Time
PCR were used to analyze the distribution and clinical relevance
of neutrophils in different microanatomical areas. The regulation
and function of neutrophils were assessed by both in vitro and
in vivo studies. The authors identiﬁed neutrophils predominant
in the peritumoral stroma rather than in the cancer nests and
correlated peritumoral neutrophils with poor OS in HCC patients.
The authors also demonstrated proinﬂammatory IL-17 as a critical
mediator of the recruitment of neutrophils into peritumoral stroma
of HCC tissues by epithelial cell-derived CXC chemokines. The accu-
mulated peritumoral neutrophils were the major source of matrix
metalloproteinase-9 in HCC tissues; this secreted protein stimu-
lated proangiogenic activity in hepatoma cells. Accordingly, high
inﬁltration of peritumoral neutrophils was positively correlated
with angiogenesis progression at the tumor-invading edge of HCC
patients. Furthermore, the authors found that selective depletion of
neutrophils effectively inhibited tumor angiogenesis and growth,
in vivo. The authors concluded that these data provided direct evi-
dence supporting the critical role of neutrophils in human HCC
tumor progression and revealed a ﬁne-tuned collaborative action
between cancer cells and immune cells in distinct tumor milieu,
which reroutes the inﬂammatory response into a tumor-promoting
direction [32].
Gao et al. evaluated cell lines and 240 patients with HCC who
received curative resection [33]. The authors demonstrated human
HCC expressed high levels of the chemokine CXCR6 also contained
an increased number of CD66b+ neutrophils and microvessels, and
the combination of CXCR6 and intratumoral neutrophils was  a
superior predictor of recurrence and survival than either marker
used alone. Multivariate analyses revealed intratumoral neutrophil
density as an independent prognostic factor for short RFS but not
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or OS. Using the combination of the two parameters, intratumoral
D66b+ neutrophils and CXCR6 were independently associated
ith short RFS and OS. Together, this ﬁnding suggests that elevated
xpression of CXCR6 promotes HCC invasiveness and a protumor
nﬂammatory environment comprising neutrophils and is associ-
ted with poor patient outcome.
The same research group subsequently evaluated expression
f the chemokine CXCR5 and intratumoral CD66b+ neutrophils in
hree independent cohorts of 919 HCC patients [34]. Multivariate
nalysis revealed that CXCL5 overexpression alone, or combined
ith the presence of intratumoral neutrophils, was an independent
rognostic factor for short OS and cumulative recurrence. Thus,
XCL5 promotes HCC cell proliferation, invasion, and intratumoral
eutrophil inﬁltration.
In intrahepatic cholangiocarcinoma Gu et al. evaluated a total
f 123 consecutive patients who underwent curative resection
35]. Multivariate analyses revealed that intratumoral CD66b+ neu-
rophils or a IL-17-producing CD4+ T-helper cell subset termed
h17-cells, and their combination, were independent prognostic
actors, which were superior to conventional clinicopathologic fea-
ures, such as intrahepatic metastasis and TNM stage. Moreover,
ntratumoral neutrophils correlated with the presence of vascular
nvasion.
Taken together, these recent studies in HCC and intrahepatic
holangiocarcinoma published within the past 2 years, have sig-
iﬁcantly added to our knowledge and emphasize the unfavorable
rognostic relevance of intratumoral neutrophils.
. Gastric and esophageal cancer
In 2012 the negative prognostic impact of tumor inﬁltrating
eutrophils in gastric adenocarcinoma after resection was  pub-
ished by Zhao et al. assessing a training group of 115 patients and a
est group of 97 patients [36]. Tumor-inﬁltrating CD15+ neutrophils
ere identiﬁed in the intratumoral stroma by immunohistochem-
stry. The density of CD15+ neutrophils was positively associated
ith lymph node metastasis, distance metastasis, and staging. Mul-
ivariate analysis showed that high density of CD15+ neutrophils
as an independent prognostic factor for poor overall survival of
astric adenocarcinoma patients. The unfavorable survival result
as veriﬁed in the test group. Thus, the presence of tumor inﬁltrat-
ng neutrophils is an independent, validated and unfavorable factor
n the prognosis of gastric adenocarcinoma patients. Previously in
002, the prognostic value of intratumoral neutrophils in gastric
arcinoma was evaluated using hematoxylin and eosin staining
nly with no immunohistochemistry [37]. In the multivariate anal-
sis, female patients with a moderate or extensive amount of tumor
nﬁltrating neutrophils had a 39% reduction in their risk of mortal-
ty, whereas male patients did not seem to be affected by the level
f tumor inﬁltrating neutrophils. These conﬂicting results empha-
ize the importance of using modern immunohistochemistry and
ther relevant techniques in the assessments of intratumoral
eutrophils.
The baseline NLR has been associated with prognosis in sev-
ral studies. Yamanaka et al. evaluated prospectively a cohort of
220 patients with advanced gastric cancer in Japan [38] and estab-
ished a signiﬁcant relationship between high NLR (≥2.5) and poor
urvival in a multivariate model. Shimada et al. evaluated a total
f 1028 patients with primary gastric adenocarcinoma who under-
ent gastrectomy [39]. On multivariate analysis, after adjusting for
umor stage, a high NLR (≥4.0) was an independent risk factor for
educed survival. Jung et al. evaluated 293 patients who had under-
one gastrectomy with curative intent [40]. A multivariate analysis
stablished a signiﬁcant relationship between high NLR (≥2.0)
nd poor OS and between high NLR (≥3.0) and poor disease-free
urvival.iology 23 (2013) 200– 207
In esophageal cancer, Sharaiha et al. performed a single-center
retrospective analysis of 295 patients who  underwent attempted
curative esophagectomy [41]. In multivariable analyses, elevated
NLR (≥5.0) was  associated with signiﬁcantly worse disease-free
survival and OS.
Recently, the ﬁrst study to demonstrate that the pretherapeutic
NLR can be used as a predictor of the chemosensitivity to neoad-
juvant chemotherapy has been published [42]. The study was a
retrospective evaluation of 83 patients undergoing neoadjuvant
chemotherapy of cisplatin and 5-FU followed by esophagectomy
for advanced esophageal cancer. The NLR was measured before
chemotherapy, and the pathologic response to chemotherapy
was  evaluated. A multivariate analysis revealed that elevated
pretreatment NLR (≥2.2) and lymph nodes metastasis were inde-
pendently associated with poor pathologic responses. Thus, the
pathologic response rate was  21% in patients with an NLR of ≥2.2
compared with 56% in the patients with an NLR < 2.2. The inter-
pretation is that high baseline NLR hinder chemotherapy effect.
These ﬁndings require larger, prospective, randomized studies for
validation.
In total, the independent prognostic role of tumor-inﬁltrating
neutrophils is now also demonstrated in gastric cancer and should
be elucidated further. Moreover, elevated preoperative NLR pre-
dicts poor prognosis following resection. It may  be utilized as a
simple, reliable prognostic factor for risk stratiﬁcation and will
provide better treatment allocation. However, it has to be men-
tioned that the cut-off values for NLR differed greatly between
studies. It would therefore be relevant for future studies to optimize
the NLR cut-off.
7. Glioma
For many years, it was believed that the brain was an “immuno-
privileged” site possessing only few immune elements. However,
in 1999 human gliomas were analyzed by Fassati et al. for the
inﬁltration of neutrophils using immunohistochemistry by stain-
ing sections for CD15-positive and myeloperoxidase-positive cells
[43]. The authors observed a marked and signiﬁcant correlation
between tumor grade and the extent of the neutrophil inﬁltration.
In the low grade tumors only 40–50% had signiﬁcant inﬁltra-
tion, while in glioblastoma multiforme over 85% of the tumors
had signiﬁcant inﬁltration. When the circulating neutrophil count
was  scored against tumor neutrophil inﬁltration, a signiﬁcant and
remarkable positive correlation was  observed between circulat-
ing neutrophil count and extent of neutrophil inﬁltration into the
tumor. The highest numbers of circulating neutrophils were seen
in the glioblastoma multiforme patients. Moreover, high-grade
glioblastoma multiforme were highly vascularized and contain
areas of necrosis. It is noteworthy that in these tumors, neutrophils
were detectable within capillaries in high numbers and were often
observed in high numbers in areas of necrosis.
More than 10 years later, Atai et al. conﬁrmed that glioblas-
toma tissue was inﬁltrated with neutrophils and macrophages and
demonstrated osteopontin is up-regulated and associated with
neutrophil and macrophage inﬁltration [44].
8. Head and neck cancer
Evaluating human head and neck squamous cell carcinoma
(HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx,
Trellakis et al. published in 2011 observations regarding the role
of neutrophils [45]. The authors observed most of T4 tumors
displayed medium or strong inﬁltration of CD66+ neutrophils,
whereas smaller and less-invasive tumors exhibited a lower degree
of neutrophil inﬁltration. The serum concentrations of CXCL8,
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CL4 and CCL5 and the peripheral blood percentages of neu-
rophils and leukocytes as well as the NLR were signiﬁcantly
igher in HNSCC patients than in healthy controls. In multivariate
nalyses of patients with advanced disease, high CD66b+ neu-
rophil tumor inﬁltration was independently associated with poor
urvival.
In 2011, An et al. published retrospective results of 363 consec-
tively, newly diagnosed, non-disseminated, and biopsy-proven
asopharyngeal carcinoma patients treated with standard curative
adiotherapy with or without chemotherapy [46]. For patients with
ocoregionally advanced disease, high NLR (>3.73) was not only an
ndependent prognostic factor for poor disease-speciﬁc survival,
istant metastasis-free survival, and loco-regional recurrence-free
urvival, but was also a predictor of response to chemoradio-
herapy. Thus, compared with radiation alone, chemoradiotherapy
igniﬁcantly improved disease-speciﬁc survival and loco-regional
ecurrence-free survival for patients with non-elevated NLR, but
ot for those with elevated NLR. This emphasizes high pre-
reatment NLR as a strong prognostic factor for poor outcome of
asopharyngeal patients.
He et al. conﬁrmed in 1410 patients with nasopharyngeal cancer
igh NLR independently associated with poor PFS in a multivariate
nalysis [47]. The authors also observed high percentage of lympho-
ytes was independently associated with a favorable PFS, whereas
 high neutrophil percentage was independently related to a poor
FS.
. GIST
Gastrointestinal stromal tumors (GISTs) are the most frequent
esenchymal tumors of the gastrointestinal tract. The spectac-
lar response to imatinib therapy is, however, time-limited and
esistance to imatinib therapy develops quite frequently in some
atients. Rutkowski et al. identiﬁed high baseline blood neutrophils
>5.0 × 109/L) as an independent negative prognostic factor for
hort PFS in 232 patients with GIST [48]. Thus, patients with pre-
matinib neutrophils > 5.0 had a 3-year PFS rate of 24.5% whereas
atients with pre-imatinib neutrophils ≤ 5.0 × 109/L had a 3-year
FS rate of 75.9%. In 934 patients with GIST Van Glabbeke et al.
valuated factors for initial resistance to imatinib, deﬁned as pro-
ression within 3 months of randomization, and late resistance
o imatinib, deﬁned as progression beyond 3 months [49]. Initial
esistance was  independently predicted by the presence of lung
nd absence of liver metastases, low hemoglobin level, and high
eutrophil count (>5 × 109/L). Late resistance was independently
redicted by high baseline neutrophil count, primary tumor out-
ide of the stomach, large tumor size, and low initial imatinib
ose. Thus, high baseline neutrophil count was  the only factor
ndependently associated with both initial and late resistance. The
uthors suggested the study identiﬁed patients for whom initial
nd/or long-term treatment needed to be improved and identiﬁed
atients who require a high initial dose. However, a subsequent
eta-analysis aiming to explore the data of the two large, random-
zed, cooperative-group studies comparing two  doses of imatinib
400 mg  daily versus twice daily) in 1640 patients with advanced
IST did not show an overall survival advantage of high-dose imat-
nib [50]. The KIT exon 9 mutation status was the only predictive
actor for a PFS beneﬁt attributed to high-dose treatment. It should
e noted that high baseline neutrophils was identiﬁed as an inde-
endent risk factor for both poor PFS and OS, and moreover, the
egative prognostic impact of neutrophils was not eliminated by
oubling the dose of imatinib.Recently, high blood neutrophils and high NLR have
een associated with short recurrence-free survival in 339
atients with primary, localized GIST treated with surgery
51].iology 23 (2013) 200– 207 205
10. Lung cancer
The ﬁrst direct evidence that neutrophils were present in the
alveolar lumen of bronchioloalveolar carcinoma and independently
were associated with a poor outcome was  published in 1998 by
Bellocq et al. [52]. Thirteen years later, Ilie et al. established the
presence of intratumoral CD66b+ neutrophils in resectable non-
small cell lung cancer (NSCLC) and correlated this ﬁnding with
a signiﬁcantly increased cumulative incidence of relapse and a
trend toward decreased OS [53]. Paesmans et al. reported on behalf
of The European Lung Cancer Working Party the ﬁrst evidence
in the literature of the independent negative prognostic impact
of blood neutrophil rate in 1052 patients with advanced NSCLC
[54] and 763 patients with small cell lung carcinoma (SCLC) [55],
all included in clinical chemotherapy trials. Moreover in SCLC, a
normal neutrophil rate, female gender, and limited disease were
independently associated with response to chemotherapy in a
multivariate analysis. Thus, high neutrophil rate had an indepen-
dent association with poor response rate and poor survival in
SCLC.
Pretreatment elevated neutrophil count (>4.5 × 109/L) was
independently associated with short PFS and OS in 388 patients
with stage IIIB or IV NSCLC in a randomized controlled trial
[56]. The authors observed the incidence of grade 3 or 4 non-
hematological toxicity within the ﬁrst three cycles of treatment was
signiﬁcantly higher in the high-neutrophil group than in the low
neutrophil group and none of the patients in the high-neutrophil
group who  experienced grade 3 or 4 non-hematological toxicity
within the ﬁrst three cycles completed the planned six cycles. Thus,
high pretreatment neutrophil count is an indicator of severe poor
prognosis.
Di Maio et al. retrospectively evaluated chemotherapy-induced
neutropenia and treatment efﬁcacy in a pooled analysis of three
randomized trials in 1265 patients with NSCLC [57] To avoid selec-
tion bias due to a higher chance of neutropenia with increasing
cycles of chemotherapy as a result of an inherently better progno-
sis, the authors used a cut-off time of 6 months after randomization
to restrict primary analyses to 436 patients who received all six
planned cycles of chemotherapy, and who  were alive 180 days after
randomization (i.e., the landmark group). Results were conﬁrmed
in 829 patients in the out-of-landmark group. In the landmark
group 47% obtained no neutropenia and 53% obtained neutrope-
nia. In the out-of-landmark group 60% obtained no neutropenia
and 40% obtained neutropenia. In multivariate analyses, neutrope-
nia was  an independent prognostic factor, both in the landmark
and out-of-landmark group. The surprising ﬁnding was  that severe
neutropenia (i.e., grade 3–4) was  no better than mild neutropenia
(i.e., grade 1–2) but that both were better than no neutropenia (i.e.,
grade 0) in terms of improved median survival in both the land-
mark group and the out-of-landmark group. In other words, it is
the presence, but not the severity, of neutropenia that is progno-
stic for favorable survival. The authors stated that prospective trials
are needed to assess whether drug dosing guided by the occur-
rence of toxic effects could improve efﬁcacy of standard regimens.
Maione et al. interpreted results from Di Maio with a new per-
spective [58]. Traditionally, the absence of chemotherapy-induced
neutropenia has been interpreted as a result of chemotherapy-
underdosing [59]. However, considering the negative prognostic
value of leucocytosis, another interpretation should be ruled out: a
proportion of the patients who  do not experience chemotherapy-
induced neutropenia may  be associated with a worst prognosis
because they may  be characterized by base-line tumor-related leu-
cocytosis and autonomous production of hematopoietic cytokines
protecting them from chemotherapy-induced neutropenia. In
other words, it may  be hypothesized that patients with elevated
baseline neutrophils are completely protected from any grade of
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hemotherapy-induced neutropenia and have a poorer prognosis,
ndependently from chemotherapy dosing.
1. Ovarian
Recently, the result of a large, multicenter, randomized trial of
at dosing versus intrapatient dose escalation of single-agent car-
oplatin as ﬁrst-line chemotherapy for advanced ovarian cancer
as been published [60]. A total of 964 patients were randomized.
ose escalation was achieved in 77% of patients who  had ≥1 cycle.
ntrapatient dose escalation of carboplatin based on nadir blood
eutrophils or thrombocytes was feasible and safe. However, it pro-
ided no improvement in PFS or OS compared with ﬂat dosing. In
ultivariate analysis, high baseline neutrophil counts had a signif-
cant adverse prognostic value whereas nadir neutrophils counts
ere not statistically signiﬁcantly associated with outcome. The
uthors concluded that baseline neutrophils over-ride nadir counts
n prognostic signiﬁcance and questioned the use of dose escalation
s a standard practice.
2. Concluding remarks
The clinical relevance of tumor-inﬁltrating neutrophils has
ecently begun to emerge. Direct associations between tumor-
nﬁltrating neutrophils and poor clinical outcome have now been
escribed for several types of human cancer. The prognostic role
f tumor-inﬁltrating neutrophils, elevated blood neutrophils and
levated blood neutrophil/lymphocyte ratio has been associated
ith poor clinical outcome, most notably in renal cell carcinoma,
elanoma, colorectal cancer, hepatocellular carcinoma, cholangio-
arcinoma, glioblastoma, GIST, gastric, esophageal, lung, ovarian
nd head and neck cancer. A striking ﬁnding is the notion that
igh baseline neutrophil count in either tumor or blood, or both,
as identiﬁed as a strong, independent risk factor for poor out-
ome and the negative prognostic impact of neutrophils was not
liminated by increasing the dose of cytokines, chemotherapy, or
argeted therapy. For several cancers, patients beneﬁt most from
herapy if baseline neutrophil was low. Thus, baseline neutrophils
ver-ride nadir counts in prognostic signiﬁcance. This has espe-
ially been shown in kidney cancer, colorectal cancer, non-small
ell lung cancer, ovarian cancer and nasopharyngeal carcinoma.
n other words, a proportion of patients who do not experience
eneﬁt from surgery or medical intervention may  be associated
ith a worst prognosis because they are characterized by base-
ine tumor-related neutrophilia protecting them from beneﬁt from
herapy.
It should been emphasized that most of these studies have
een published within the last few years, demonstrating an inde-
endent prognostic role of neutrophils in blood or tumor, or
oth, after correcting for well-known clinical and pathological
eatures, highlighting the increasing importance and relevance
f neutrophils in cancer biology [61] (Table 1). Further stud-
es are recommended, examining the therapeutic implication of
he adverse prognostic signiﬁcance of high neutrophil count.
he existence and properties of N1 and N2 neutrophils in
uman cancer related inﬂammation need to be carefully inves-
igated to provide a basis for new diagnostic and therapeutic
trategies [62].onﬂict of interest
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